Spruce Biosciences, Inc.
SPRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001683553
No open-market purchases or sales by Spruce Biosciences, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $116.3M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Spruce Biosciences, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 38 | 36 | −2 |
| Shares | 16.4M | 18.0M | +1.67M (+10.2%) |
| Value | $28.5M | $24.7M | −$3.75M (−13.2%) |
New holders (3)
Institutions that held Spruce Biosciences, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Abingworth LLP | 1,792,518 | $2.47M | 0.85% |
| Bailard, Inc. | 21,166 | $29.0K | 0.00% |
| Dimensional Fund Advisors LP | 11,805 | $16.0K | 0.00% |
Sold out (5)
Institutions that held Spruce Biosciences, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Virtu Financial LLC | 15,738 | $27.0K |
| Legal & General Group Plc | 782 | $1.00K |
| Citigroup Inc | 393 | $1.00K |
| New York State Common Retirement Fund | 77 | $0 |
| Credit Suisse AG | 5 | $0 |